Press release
Duchenne Muscular Dystrophy Therapeutics Market Key Players : Bristol-Myers Squibb Company, FibroGen, Inc., ITALFARMACO S.p.A., Marathon Pharmaceuticals, LLC, NS Pharma, Inc, PTC Therapeutics, Inc.
Duchenne muscular dystrophy (DMD) therapeutics helps treat genetic disorder caused due to absence of dystrophin, a protein in the body. The symptoms of the disease include weakness in the muscles of the hips, pelvic area, thighs, and shoulders, and later in the muscles of arms, legs, and trunk.Key players in the market include Bristol-Myers Squibb Company, FibroGen, Inc., ITALFARMACO S.p.A., Marathon Pharmaceuticals, LLC, NS Pharma, Inc, PTC Therapeutics, Inc., Pfizer Inc., ReveraGen BioPharma, Inc., Santhera Pharmaceuticals, and Sarepta Therapeutics, Inc.
Get Sample PDF Brochure : https://www.alliedmarketresearch.com/request-toc-and-sample/4102
Factors such as, increase in incidences of Duchenne muscular dystrophy and introduction of specific guidance for development for Duchenne muscular dystrophy drugs by FDA drive the market growth. However, low rate of treatment due to delayed diagnosis and prediction hinder the market growth. Moreover, fast track approval of these drugs by FDA and untapped growth opportunities in the emerging economies of Asia-Pacific and LAMEA are expected to fuel the market growth during the forecast period.
The global Duchenne muscular dystrophy therapeutics market is segmented on the basis of type, end user, and region. On the basis of type, it is bifurcated into pain management drugs and corticosteroids. Corticosteroids are further sub-segmented into prednisolone, prednisone, and deflazacort. On the basis of end-user, it is divided into hospitals, clinics, and home care settings. By geography, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Key Benefits
• The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2016 to 2023, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
• Extensive analysis by product helps understand various therapeutics used for Duchenne dystrophy.
• Comprehensive analysis of all geographical regions is provided, which helps determine the prevailing opportunities.
• Key players are profiled and their strategies are analyzed thoroughly, which elucidates the competitive outlook of the global market.
Duchenne Muscular Dystrophy Therapeutics Market Key Segments:
By Type
• Pain Management Drugs
• Corticosteroids
• Prednisolone
• Prednisone
• Deflazacort
By End User
• Hospitals
• Clinics
• Home Care Settings
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o Rest of Asia-Pacific
• LAMEA
o Brazil
o South Africa
o Saudi Arabia
o Rest of LAMEA
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
David C
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Duchenne Muscular Dystrophy Therapeutics Market Key Players : Bristol-Myers Squibb Company, FibroGen, Inc., ITALFARMACO S.p.A., Marathon Pharmaceuticals, LLC, NS Pharma, Inc, PTC Therapeutics, Inc. here
News-ID: 1293010 • Views: …
More Releases from Allied Market Research

Global Urinary Drainage Bags Market: Trends, Growth, and Insights to 2031
The global urinary drainage bags market is experiencing robust growth, with its market size valued at $1.4billion in 2021 and projected to reach $2billion by 2031. This expansion represents a compound annual growth rate (CAGR) of 3.8% from 2021 to 2031, highlighting the increasing demand for these essential medical devices.
Get a Sample Copy of this Report: https://www.alliedmarketresearch.com/request-sample/A17529
What Are Urinary Drainage Bags?
Urinary drainage bags are specialized medical devices designed to collect…

Cream Powder Market to Reach $8.9 Billion by 2031 with 6.4% CAGR
The global cream powder industry was estimated at $4.8 billion in 2021 and is expected to hit $8.9 billion by 2031, registering a CAGR of 6.4% from 2022 to 2031.
The cream powder market is experiencing growth due to various factors, including the increasing popularity of bakeries and HoReCa (hotels, restaurants, and cafes) and rising consumer demand for natural products. The dairy-based segment is a significant contributor to the market's growth…

Micro Drone Market Valued at $6.71 Billion in 2020, Expected to Reach $28.91 Bil …
The global micro drone industry generated $6.71 billion in 2020, and is expected to reach $28.91 billion in 2030, witnessing a CAGR of 17.2% from 2021 to 2030. The report provides an extensive analysis of changing market dynamics, top segments, top investment pockets, regional landscape, value chain, and competitive scenario.
Increased operational efficiency and rise in demand for improved surveillance drive the growth of the global micro drone market. However, strict…

Microwavable Foods Market to reach $230.93 billion by 2031, growing at a CAGR of …
The global microwaveable foods industry was accounted for $120.45 billion in 2020, and is expected to reach $230.93 billion by 2031, growing at a CAGR of 5.6% from 2022 to 2031.
Rise in popularity of fast-food restaurants and large population base coupled with increase in number of quick-service restaurants drive the global microwaveable foods market. However, lack of awareness about microwavable foods hinders the market growth. On the contrary, rise in…
More Releases for Duchenne
Emerging Trends Influencing The Growth Of The Duchenne Muscular Dystrophy (DMD) …
The Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Expected to Be by 2034?
In recent times, the market size for Duchenne Muscular Dystrophy (DMD) therapeutics has seen a significant…
Rising Prevalence Of Chronic Diseases Fuels Growth In The Duchenne Muscular Dyst …
What industry-specific factors are fueling the growth of the duchenne muscular dystrophy market?
The rise in chronic diseases is projected to stimulate the expansion of the Duchenne muscular dystrophy market in the coming years. Chronic diseases are health complications that endure for a minimum of a year. Duchenne muscular dystrophy is instrumental in the increase of chronic diseases as it addresses the unique therapeutic requirements of those suffering from this genetic…
Shaping the Duchenne Muscular Dystrophy (DMD) Therapeutics Market in 2025: Bit B …
How Big Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Expected to Be, and What Will Its Growth Rate Be?
The Duchenne muscular dystrophy (DMD) therapeutics market will grow from $11.95 billion in 2024 to $16.45 billion in 2025, at a CAGR of 37.6%. The growth is attributed to the increasing prevalence of Duchenne muscular dystrophy, rising awareness of treatment options, healthcare spending, and government initiatives.
The Duchenne muscular dystrophy (DMD) therapeutics…
Duchenne Muscular Dystrophy Pipeline Outlook Report 2024
DelveInsight's, "Duchenne Muscular Dystrophy Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Duchenne Muscular Dystrophy pipeline landscape. It covers the Duchenne Muscular Dystrophy pipeline drug profiles, including Duchenne Muscular Dystrophy clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
…
Duchenne Muscular Dystrophy Treatmcent Market
Global Duchenne Muscular Dystrophy Treatmcent Market Set for Robust Growth During Forecast Period
The global Duchenne Muscular Dystrophy Treatment Market is poised to witness significant growth at a high Compound Annual Growth Rate (CAGR) during the forecast period of 2023 to 2030. Duchenne muscular dystrophy (DMD) stands as a genetic disorder marked by progressive muscle degeneration and weakness, with therapeutics aimed at addressing the absence of dystrophin, a crucial protein in…
Duchenne Muscular Dystrophy (DMD) Drugs Market Report
As per the research conducted by GME, the Duchenne Muscular Dystrophy (DMD) Drugs Market will grow with a CAGR value of 41.3 percent by 2026. The global market for Duchenne muscular dystrophy is foreseen to grow due to accelerated research and development activities, expanded patient awareness for effective treatments, and the launch of new medications Moreover, the disease's increasing prominence is likely to drive the global duchenne muscular dystrophy market…